- Home
- WRLD vs MYGN Comparison
WRLD vs MYGN Comparison
Compare WRLD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- MYGN
- Stock Information
- Founded
- WRLD 1962
- MYGN 1991
- Country
- WRLD United States
- MYGN United States
- Employees
- WRLD N/A
- MYGN N/A
- Industry
- WRLD Finance: Consumer Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WRLD Finance
- MYGN Health Care
- Exchange
- WRLD Nasdaq
- MYGN Nasdaq
- Market Cap
- WRLD 656.7M
- MYGN 744.7M
- IPO Year
- WRLD 1991
- MYGN 1995
- Fundamental
- Price
- WRLD $124.86
- MYGN $7.64
- Analyst Decision
- WRLD
- MYGN Hold
- Analyst Count
- WRLD 0
- MYGN 16
- Target Price
- WRLD N/A
- MYGN $20.17
- AVG Volume (30 Days)
- WRLD 34.1K
- MYGN 1.0M
- Earning Date
- WRLD 05-01-2025
- MYGN 05-06-2025
- Dividend Yield
- WRLD N/A
- MYGN N/A
- EPS Growth
- WRLD 29.61
- MYGN N/A
- EPS
- WRLD 14.42
- MYGN N/A
- Revenue
- WRLD $558,622,726.00
- MYGN $837,600,000.00
- Revenue This Year
- WRLD N/A
- MYGN $2.99
- Revenue Next Year
- WRLD $3.69
- MYGN $8.36
- P/E Ratio
- WRLD $8.66
- MYGN N/A
- Revenue Growth
- WRLD N/A
- MYGN 11.21
- 52 Week Low
- WRLD $101.85
- MYGN $7.35
- 52 Week High
- WRLD $161.63
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- WRLD 50.84
- MYGN 28.54
- Support Level
- WRLD $120.99
- MYGN $7.69
- Resistance Level
- WRLD $124.26
- MYGN $8.27
- Average True Range (ATR)
- WRLD 7.14
- MYGN 0.56
- MACD
- WRLD 0.48
- MYGN 0.04
- Stochastic Oscillator
- WRLD 74.45
- MYGN 17.37
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.